filings.toolsItem 1. Financial Statements
153K characters. Original on sec.gov · Markdown
Item 1. Financial Statements
Medtronic plc
Consolidated Statements of Income
(Unaudited)
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions, except per share data) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||
| Net sales | $ | 8,292 | $ | 8,089 | $ | 24,610 | $ | 23,775 | |||||||||||||||
| Costs and expenses: | |||||||||||||||||||||||
| Cost of products sold, excluding amortization of intangible assets | 2,779 | 2,782 | 8,485 | 8,172 | |||||||||||||||||||
| Research and development expense | 675 | 695 | 2,048 | 2,060 | |||||||||||||||||||
| Selling, general, and administrative expense | 2,717 | 2,673 | 8,129 | 7,971 | |||||||||||||||||||
| Amortization of intangible assets | 416 | 419 | 1,243 | 1,274 | |||||||||||||||||||
| Restructuring charges, net | 43 | 20 | 120 | 114 | |||||||||||||||||||
| Certain litigation charges, net | 22 | — | 104 | 105 | |||||||||||||||||||
| Other operating (income) expense, net | (5) | 17 | (38) | (13) | |||||||||||||||||||
| Operating profit | 1,646 | 1,483 | 4,519 | 4,091 | |||||||||||||||||||
| Other non-operating income, net | (72) | (177) | (403) | (407) | |||||||||||||||||||
| Interest expense, net | 179 | 188 | 555 | 517 | |||||||||||||||||||
| Income before income taxes | 1,540 | 1,472 | 4,367 | 3,982 | |||||||||||||||||||
| Income tax provision | 237 | 135 | 737 | 936 | |||||||||||||||||||
| Net income | 1,303 | 1,337 | 3,630 | 3,045 | |||||||||||||||||||
| Net income attributable to noncontrolling interests | (9) | (15) | (24) | (23) | |||||||||||||||||||
| Net income attributable to Medtronic | $ | 1,294 | $ | 1,322 | $ | 3,606 | $ | 3,022 | |||||||||||||||
| Basic earnings per share | $ | 1.01 | $ | 0.99 | $ | 2.80 | $ | 2.27 | |||||||||||||||
| Diluted earnings per share | $ | 1.01 | $ | 0.99 | $ | 2.79 | $ | 2.27 | |||||||||||||||
| Basic weighted average shares outstanding | 1,282.4 | 1,329.7 | 1,286.7 | 1,330.1 | |||||||||||||||||||
| Diluted weighted average shares outstanding | 1,286.2 | 1,331.7 | 1,290.6 | 1,332.4 |
The accompanying notes are an integral part of these consolidated financial statements.
Medtronic plc
Consolidated Statements of Comprehensive Income
(Unaudited)
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||
| Net income | $ | 1,303 | $ | 1,337 | $ | 3,630 | $ | 3,045 | |||||||||||||||
| Other comprehensive income (loss), net of tax: | |||||||||||||||||||||||
| Unrealized (loss) gain on investment securities | (1) | 111 | 110 | 73 | |||||||||||||||||||
| Translation adjustment | (663) | 450 | (444) | (461) | |||||||||||||||||||
| Net investment hedge | 780 | (424) | 610 | 348 | |||||||||||||||||||
| Net change in retirement obligations | 1 | 2 | 3 | 6 | |||||||||||||||||||
| Unrealized gain (loss) on cash flow hedges | 292 | (220) | 200 | 74 | |||||||||||||||||||
| Other comprehensive income (loss) | 409 | (81) | 478 | 39 | |||||||||||||||||||
| Comprehensive income including noncontrolling interests | 1,712 | 1,257 | 4,108 | 3,084 | |||||||||||||||||||
| Comprehensive income attributable to noncontrolling interests | (7) | (17) | (23) | (23) | |||||||||||||||||||
| Comprehensive income attributable to Medtronic | $ | 1,705 | $ | 1,240 | $ | 4,085 | $ | 3,062 |
The accompanying notes are an integral part of these consolidated financial statements.
Medtronic plc
Consolidated Balance Sheets
(Unaudited)
| (in millions) | January 24, 2025 | April 26, 2024 | |||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 1,240 | $ | 1,284 | |||||||
| Investments | 6,682 | 6,721 | |||||||||
| Accounts receivable, less allowances and credit losses of $204 and $173, respectively | 6,115 | 6,128 | |||||||||
| Inventories | 5,610 | 5,217 | |||||||||
| Other current assets | 2,865 | 2,584 | |||||||||
| Total current assets | 22,513 | 21,935 | |||||||||
| Property, plant, and equipment, net | 6,593 | 6,131 | |||||||||
| Goodwill | 40,819 | 40,986 | |||||||||
| Other intangible assets, net | 12,184 | 13,225 | |||||||||
| Tax assets | 3,614 | 3,657 | |||||||||
| Other assets | 4,250 | 4,047 | |||||||||
| Total assets | $ | 89,973 | $ | 89,981 | |||||||
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Current debt obligations | $ | 2,622 | $ | 1,092 | |||||||
| Accounts payable | 2,286 | 2,410 | |||||||||
| Accrued compensation | 2,281 | 2,375 | |||||||||
| Accrued income taxes | 1,125 | 1,330 | |||||||||
| Other accrued expenses | 3,526 | 3,582 | |||||||||
| Total current liabilities | 11,840 | 10,789 | |||||||||
| Long-term debt | 23,985 | 23,932 | |||||||||
| Accrued compensation and retirement benefits | 1,063 | 1,101 | |||||||||
| Accrued income taxes | 1,485 | 1,859 | |||||||||
| Deferred tax liabilities | 452 | 515 | |||||||||
| Other liabilities | 1,533 | 1,365 | |||||||||
| Total liabilities | 40,358 | 39,561 | |||||||||
| Commitments and contingencies (Note 16) | |||||||||||
| Shareholders’ equity: | |||||||||||
| Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,283,266,154 and 1,311,337,531 shares issued and outstanding, respectively | — | — | |||||||||
| Additional paid-in capital | 20,910 | 23,129 | |||||||||
| Retained earnings | 31,317 | 30,403 | |||||||||
| Accumulated other comprehensive loss | (2,839) | (3,318) | |||||||||
| Total shareholders’ equity | 49,387 | 50,214 | |||||||||
| Noncontrolling interests | 228 | 206 | |||||||||
| Total equity | 49,615 | 50,420 | |||||||||
| Total liabilities and equity | $ | 89,973 | $ | 89,981 |
The accompanying notes are an integral part of these consolidated financial statements.
Medtronic plc
Consolidated Statements of Equity
(Unaudited)
| Ordinary Shares | Additional Paid-in Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Total Shareholders’ Equity | Noncontrolling Interests | Total Equity | ||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | Number | Par Value | ||||||||||||||||||||||||||||||||||||||||||||||||
| April 26, 2024 | 1,311 | $ | — | $ | 23,129 | $ | 30,403 | $ | (3,318) | $ | 50,214 | $ | 206 | $ | 50,420 | |||||||||||||||||||||||||||||||||||
| Net income | — | — | — | 1,042 | — | 1,042 | 6 | 1,049 | ||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss | — | — | — | — | (92) | (92) | — | (92) | ||||||||||||||||||||||||||||||||||||||||||
| Dividends to shareholders ($0.70 per ordinary share) | — | — | — | (898) | — | (898) | — | (898) | ||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares under stock purchase and award plans | 1 | — | 87 | — | — | 87 | — | 87 | ||||||||||||||||||||||||||||||||||||||||||
| Repurchase of ordinary shares | (30) | — | (2,489) | — | — | (2,489) | — | (2,489) | ||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | 83 | — | — | 83 | — | 83 | ||||||||||||||||||||||||||||||||||||||||||
| July 26, 2024 | 1,282 | $ | — | $ | 20,810 | $ | 30,547 | $ | (3,410) | $ | 47,947 | $ | 213 | $ | 48,160 | |||||||||||||||||||||||||||||||||||
| Net income | — | — | — | 1,270 | — | 1,270 | 9 | 1,278 | ||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income | — | — | — | — | 161 | 161 | — | 161 | ||||||||||||||||||||||||||||||||||||||||||
| Dividends to shareholders ($0.70 per ordinary share) | — | — | — | (897) | — | (897) | — | (897) | ||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares under stock purchase and award plans | 3 | — | 103 | — | — | 103 | — | 103 | ||||||||||||||||||||||||||||||||||||||||||
| Repurchase of ordinary shares | (3) | — | (248) | — | — | (248) | — | (248) | ||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | 159 | — | — | 159 | — | 159 | ||||||||||||||||||||||||||||||||||||||||||
| October 25, 2024 | 1,283 | $ | — | $ | 20,824 | $ | 30,919 | $ | (3,250) | $ | 48,494 | $ | 222 | $ | 48,716 | |||||||||||||||||||||||||||||||||||
| Net income | — | — | — | 1,294 | — | 1,294 | 9 | 1,303 | ||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income (loss) | — | — | — | — | 411 | 411 | (1) | 409 | ||||||||||||||||||||||||||||||||||||||||||
| Dividends to shareholders ($0.70 per ordinary share) | — | — | — | (897) | — | (897) | — | (897) | ||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares under stock purchase and award plans | 3 | — | 152 | — | — | 152 | — | 152 | ||||||||||||||||||||||||||||||||||||||||||
| Repurchase of ordinary shares | (2) | — | (164) | — | — | (164) | — | (164) | ||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | 98 | — | — | 98 | — | 98 | ||||||||||||||||||||||||||||||||||||||||||
| Changes to noncontrolling ownership interests | — | — | — | — | — | — | (2) | (2) | ||||||||||||||||||||||||||||||||||||||||||
| January 24, 2025 | 1,283 | $ | — | $ | 20,910 | $ | 31,317 | $ | (2,839) | $ | 49,387 | $ | 228 | $ | 49,615 |
| Ordinary Shares | Additional Paid-in Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Total Shareholders’ Equity | Noncontrolling Interests | Total Equity | ||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | Number | Par Value | ||||||||||||||||||||||||||||||||||||||||||||||||
| April 28, 2023 | 1,331 | $ | — | $ | 24,590 | $ | 30,392 | $ | (3,499) | $ | 51,483 | $ | 182 | $ | 51,665 | |||||||||||||||||||||||||||||||||||
| Net income | — | — | — | 791 | — | 791 | 6 | 797 | ||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss | — | — | — | — | (175) | (175) | — | (175) | ||||||||||||||||||||||||||||||||||||||||||
| Dividends to shareholders ($0.69 per ordinary share) | — | — | — | (918) | — | (918) | — | (918) | ||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares under stock purchase and award plans | 1 | — | 73 | — | — | 73 | — | 73 | ||||||||||||||||||||||||||||||||||||||||||
| Repurchase of ordinary shares | (2) | — | (148) | — | — | (148) | — | (148) | ||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | 73 | — | — | 73 | — | 73 | ||||||||||||||||||||||||||||||||||||||||||
| July 28, 2023 | 1,330 | $ | — | $ | 24,587 | $ | 30,265 | $ | (3,674) | $ | 51,178 | $ | 188 | $ | 51,366 | |||||||||||||||||||||||||||||||||||
| Net income | — | — | — | 909 | — | 909 | 2 | 911 | ||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income (loss) | — | — | — | — | 297 | 297 | (2) | 295 | ||||||||||||||||||||||||||||||||||||||||||
| Dividends to shareholders ($0.69 per ordinary share) | — | — | — | (918) | — | (918) | — | (918) | ||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares under stock purchase and award plans | 2 | — | 35 | — | — | 35 | — | 35 | ||||||||||||||||||||||||||||||||||||||||||
| Repurchase of ordinary shares | (2) | — | (189) | — | — | (189) | — | (189) | ||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | 146 | — | — | 146 | — | 146 | ||||||||||||||||||||||||||||||||||||||||||
| October 27, 2023 | 1,330 | $ | — | $ | 24,580 | $ | 30,256 | $ | (3,377) | $ | 51,460 | $ | 187 | $ | 51,647 | |||||||||||||||||||||||||||||||||||
| Net income | — | — | — | 1,322 | — | 1,322 | 15 | 1,337 | ||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive (loss) income | — | — | — | — | (82) | (82) | 1 | (81) | ||||||||||||||||||||||||||||||||||||||||||
| Dividends to shareholders ($0.69 per ordinary share) | — | — | — | (917) | — | (917) | — | (917) | ||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares under stock purchase and award plans | 1 | — | 49 | — | — | 49 | — | 49 | ||||||||||||||||||||||||||||||||||||||||||
| Repurchase of ordinary shares | (2) | — | (124) | — | — | (124) | — | (124) | ||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | 85 | — | — | 85 | — | 85 | ||||||||||||||||||||||||||||||||||||||||||
| January 26, 2024 | 1,330 | $ | — | $ | 24,589 | $ | 30,661 | $ | (3,459) | $ | 51,792 | $ | 204 | $ | 51,996 |
The accompanying notes are an integral part of these consolidated financial statements.
Medtronic plc
Consolidated Statements of Cash Flows
(Unaudited)
| Nine months ended | |||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | |||||||||
| Operating Activities: | |||||||||||
| Net income | $ | 3,630 | $ | 3,045 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 2,021 | 1,993 | |||||||||
| Provision for credit losses | 96 | 62 | |||||||||
| Deferred income taxes | (81) | (250) | |||||||||
| Stock-based compensation | 340 | 303 | |||||||||
| Other, net | 14 | 265 | |||||||||
| Change in operating assets and liabilities, net of acquisitions and divestitures: | |||||||||||
| Accounts receivable, net | (184) | (140) | |||||||||
| Inventories | (478) | (530) | |||||||||
| Accounts payable and accrued liabilities | (157) | (253) | |||||||||
| Other operating assets and liabilities | (685) | (485) | |||||||||
| Net cash provided by operating activities | 4,516 | 4,010 | |||||||||
| Investing Activities: | |||||||||||
| Acquisitions, net of cash acquired | (98) | (74) | |||||||||
| Additions to property, plant, and equipment | (1,400) | (1,161) | |||||||||
| Purchases of investments | (6,093) | (5,422) | |||||||||
| Sales and maturities of investments | 6,255 | 5,142 | |||||||||
| Other investing activities, net | (111) | (155) | |||||||||
| Net cash used in investing activities | (1,447) | (1,670) | |||||||||
| Financing Activities: | |||||||||||
| Change in current debt obligations, net | (1,070) | 1,010 | |||||||||
| Issuance of long-term debt | 3,209 | — | |||||||||
| Dividends to shareholders | (2,692) | (2,753) | |||||||||
| Issuance of ordinary shares | 400 | 206 | |||||||||
| Repurchase of ordinary shares | (2,961) | (510) | |||||||||
| Other financing activities, net | 96 | (44) | |||||||||
| Net cash used in financing activities | (3,018) | (2,091) | |||||||||
| Effect of exchange rate changes on cash and cash equivalents | (95) | (170) | |||||||||
| Net change in cash and cash equivalents | (44) | 80 | |||||||||
| Cash and cash equivalents at beginning of period | 1,284 | 1,543 | |||||||||
| Cash and cash equivalents at end of period | $ | 1,240 | $ | 1,623 | |||||||
| Supplemental Cash Flow Information | |||||||||||
| Cash paid for: | |||||||||||
| Income taxes | $ | 1,515 | $ | 1,403 | |||||||
| Interest | 567 | 568 | |||||||||
The accompanying notes are an integral part of these consolidated financial statements.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
1. Basis of Presentation
The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year.
Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.
The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation. Amounts reported in millions within this quarterly report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.
The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended April 26, 2024. The Company’s fiscal years 2025, 2024, and 2023 will end or ended on April 25, 2025, April 26, 2024, and April 28, 2023, respectively.
2. New Accounting Pronouncements
Recently Adopted Accounting Standards
As of January 24, 2025, there have been no newly adopted accounting pronouncements that materially impact our consolidated financial statements. Refer to the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024 for pronouncements recently adopted.
Not Yet Adopted Accounting Standards
Segment Reporting
In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.
Income Taxes
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.
Disaggregation of Income Statement Expenses
In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Topic 220-40), which requires tabular disclosures disaggregating certain costs and expenses within relevant income statement captions. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2028 for our annual report and for interim periods starting in fiscal year 2029. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
3. Revenue
The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, hypertension, neurological surgery technologies, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, ear, nose, and throat conditions, urological and digestive disorders, advanced and general surgical care products, respiratory and monitoring solutions, and diabetes conditions. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. Certain prior period net sales have been recast to conform to the new operating segment structure in the fourth quarter of fiscal year 2024. Refer to Note 17 to the consolidated financial statements for additional information regarding the Company's reporting structure. In addition, starting in the first quarter of fiscal year 2025, the Company combined the non-U.S. developed markets and the emerging markets into an international market geography. Prior period net sales have been recast to conform to the new presentation.
The table below illustrates net sales by segment and division and by market geography for the three and nine months ended January 24, 2025 and January 26, 2024. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries.
| World wide | |||||||||||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||
| Cardiac Rhythm & Heart Failure | $ | 1,545 | $ | 1,470 | $ | 4,659 | $ | 4,408 | |||||||||||||||
| Structural Heart & Aortic | 874 | 843 | 2,610 | 2,475 | |||||||||||||||||||
| Coronary & Peripheral Vascular | 618 | 616 | 1,876 | 1,818 | |||||||||||||||||||
| Cardiovascular | 3,037 | 2,929 | 9,145 | 8,702 | |||||||||||||||||||
| Cranial & Spinal Technologies | 1,250 | 1,204 | 3,632 | 3,465 | |||||||||||||||||||
| Specialty Therapies | 732 | 726 | 2,181 | 2,126 | |||||||||||||||||||
| Neuromodulation | 476 | 425 | 1,413 | 1,270 | |||||||||||||||||||
| Neuroscience | 2,458 | 2,355 | 7,226 | 6,861 | |||||||||||||||||||
| Surgical & Endoscopy | 1,596 | 1,616 | 4,790 | 4,803 | |||||||||||||||||||
| Acute Care & Monitoring | 476 | 495 | 1,406 | 1,416 | |||||||||||||||||||
| Medical Surgical | 2,072 | 2,112 | 6,196 | 6,219 | |||||||||||||||||||
| Diabetes | 694 | 640 | 2,027 | 1,829 | |||||||||||||||||||
| Reportable segment net sales | 8,260 | 8,035 | 24,593 | 23,610 | |||||||||||||||||||
| Other operating segment(1) | 32 | 53 | 106 | 164 | |||||||||||||||||||
| Other adjustments(2) | — | — | (90) | — | |||||||||||||||||||
| Total net sales | $ | 8,292 | $ | 8,089 | $ | 24,610 | $ | 23,775 |
| U.S. | International | U.S. | International | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cardiovascular | $ | 1,405 | $ | 1,373 | $ | 1,632 | $ | 1,556 | $ | 4,242 | $ | 4,149 | $ | 4,904 | $ | 4,552 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Neuroscience | 1,689 | 1,556 | 769 | 799 | 4,931 | 4,614 | 2,295 | 2,248 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical Surgical | 893 | 947 | 1,180 | 1,164 | 2,718 | 2,763 | 3,478 | 3,456 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Diabetes | 236 | 224 | 457 | 416 | 683 | 629 | 1,344 | 1,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reportable segment net sales | 4,223 | 4,100 | 4,038 | 3,935 | 12,573 | 12,154 | 12,020 | 11,456 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other operating segment(1) | 15 | 20 | 17 | 34 | 51 | 65 | 55 | 99 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other adjustments(2) | — | — | — | — | — | — | (90) | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total net sales | $ | 4,237 | $ | 4,120 | $ | 4,055 | $ | 3,968 | $ | 12,624 | $ | 12,219 | $ | 11,986 | $ | 11,555 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1)Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested.
(2)Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases to revenue. At January 24, 2025, $1.0 billion of rebates were classified as other accrued expenses, and $625 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheet. At April 26, 2024, $1.0 billion of rebates were classified as other accrued expenses, and $574 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheet.
Deferred Revenue and Remaining Performance Obligations
Deferred revenue at January 24, 2025 and April 26, 2024 was $462 million and $453 million, respectively. At January 24, 2025 and April 26, 2024, $369 million and $352 million was included in other accrued expenses, respectively, and $93 million and $101 million was included in other liabilities, respectively. During the nine months ended January 24, 2025, the Company recognized $251 million of revenue that was included in deferred revenue as of April 26, 2024. During the nine months ended January 26, 2024, the Company recognized $274 million of revenue that was included in deferred revenue as of April 28, 2023.
Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At January 24, 2025, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately $0.4 billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next three years.
4. Acquisitions and Dispositions
Acquisition Activity
During the three and nine months ended January 24, 2025 and the fiscal year ended April 26, 2024, the Company had acquisitions that were accounted for as business combinations. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future, yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The results of operations of acquired businesses have been included in the Company's consolidated statements of income since the date each business was acquired. The results of operations of acquired businesses and the pro forma impact of the acquisitions were not significant, either individually or in the aggregate, to the consolidated results of the Company for the three and nine months ended January 24, 2025 and the fiscal year ended April 26, 2024. For the three and nine months ended January 24, 2025 and the fiscal year ended April 26, 2024, purchase price allocation adjustments were not significant.
Fiscal year 2025
The acquisition date fair value of net assets acquired during the three months ended January 24, 2025 was $128 million. Based on preliminary valuations, assets acquired were primarily comprised of $108 million of goodwill and $50 million of IPR&D. The goodwill is not deductible for tax purposes. The Company recognized $20 million of non-cash contingent consideration liabilities in connection with the business combination during the three months ended January 24, 2025, which comprised of other milestone-based payments.
Fiscal year 2024
The acquisition date fair value of net assets acquired during the fiscal year ended April 26, 2024 was $335 million. Based on preliminary valuations, assets acquired were primarily comprised of $131 million of goodwill, $150 million of IPR&D, and $29 million of technology-based intangible assets with estimated useful lives of 10 years. For tax purposes, $51 million of goodwill is deductible while $80 million is not deductible. The IPR&D was placed into service as a definite-lived intangible asset during the second quarter of fiscal year 2025. The Company recognized $30 million of non-cash contingent consideration liabilities in connection with these business combinations during the fiscal year ended April 26, 2024, which are comprised of revenue and product development milestone-based payments.
Contingent Consideration
Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within other operating (income) expense, net in the consolidated statements of income.
The fair value of contingent consideration liabilities at January 24, 2025 and April 26, 2024 was $85 million and $149 million, respectively. At January 24, 2025, $34 million was recorded in other accrued expenses, and $51 million was recorded in other liabilities in the consolidated balance sheet. At April 26, 2024, $96 million was recorded in other accrued expenses, and $53 million was recorded in other liabilities in the consolidated balance sheet.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||
| Beginning balance | $ | 124 | $ | 220 | $ | 149 | $ | 206 | |||||||||||||||
| Purchase price contingent consideration | 20 | — | 20 | 25 | |||||||||||||||||||
| Payments | (69) | (69) | (83) | (72) | |||||||||||||||||||
| Change in fair value | 10 | 21 | (1) | 14 | |||||||||||||||||||
| Ending balance | $ | 85 | $ | 172 | $ | 85 | $ | 172 |
The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:
| Fair Value at | ||||||||||||||||||||||||||||||||
| (in millions) | January 24, 2025 | Unobservable Input | Range | Weighted Average (1) | ||||||||||||||||||||||||||||
| Revenue and other performance-based payments | $56 | Discount rate | 16.5% - 28.2% | 22.4% | ||||||||||||||||||||||||||||
| Projected fiscal year of payment | 2025 - 2029 | 2027 | ||||||||||||||||||||||||||||||
| Product development and other milestone-based payments | $30 | Discount rate | 5.5% | 5.5% | ||||||||||||||||||||||||||||
| Projected fiscal year of payment | 2025 - 2028 | 2027 |
(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.
On April 1, 2023, the Company and DaVita Inc. (“DaVita”) completed the transaction for the Company to sell half of its Renal Care Solutions (RCS) business. In connection with the sale, the Company may be entitled to receive additional consideration based on the achievement of certain revenue, regulatory, and profitability milestones, with potential payouts starting in fiscal year 2026 through 2029. The fair value of the contingent consideration receivable at January 24, 2025 and April 26, 2024 was $61 million and $58 million, and was recorded in other assets in the consolidated balance sheet.
The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||
| Beginning balance | $ | 61 | $ | 152 | $ | 58 | $ | 195 | |||||||||||||||
| Change in fair value | — | (2) | 3 | (45) | |||||||||||||||||||
| Ending balance | $ | 61 | $ | 150 | $ | 61 | $ | 150 |
5. Restructuring and Other Costs
Restructuring and associated costs for the three and nine months ended January 24, 2025 were $46 million and $154 million, respectively, as compared to $55 million and $237 million for the three and nine months ended January 26, 2024, respectively. Restructuring and associated costs primarily related to employee termination benefits and facility consolidations to support cost reduction initiatives.
Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated. Associated and other costs primarily include salaries and wages of employees that are fully-dedicated to restructuring activities, consulting expenses, and asset write-offs.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
The following table presents the classification of restructuring and associated costs in the consolidated statements of income:
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||
| Cost of products sold | $ | 4 | $ | 12 | $ | 24 | $ | 43 | |||||||||||||||
| Selling, general, and administrative expenses | — | 23 | 10 | 80 | |||||||||||||||||||
| Restructuring charges, net | 43 | 20 | 120 | 114 | |||||||||||||||||||
| Total restructuring and associated costs | $ | 46 | $ | 55 | $ | 154 | $ | 237 |
The following table summarizes the activity for the nine months ended January 24, 2025:
| (in millions) | Employee Termination Benefits | Associated and Other Costs | Total | ||||||||||||||||||||||||||
| April 26, 2024 | $ | 136 | $ | 11 | $ | 147 | |||||||||||||||||||||||
| Charges | 127 | 40 | 167 | ||||||||||||||||||||||||||
| Cash payments | (189) | (39) | (228) | ||||||||||||||||||||||||||
| Settled non-cash | — | (10) | (10) | ||||||||||||||||||||||||||
| Accrual adjustments(1) | (13) | — | (13) | ||||||||||||||||||||||||||
| January 24, 2025 | $ | 61 | $ | 2 | $ | 63 | |||||||||||||||||||||||
(1)Accrual adjustments primarily relate to certain employees identified for termination, finding other positions within the Company.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
6. Financial Instruments
Debt Securities
The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at January 24, 2025 and April 26, 2024:
| January 24, 2025 | |||||||||||||||||||||||||||||||||||
| Valuation | Balance Sheet Classification | ||||||||||||||||||||||||||||||||||
| (in millions) | Cost | Unrealized Gains | Unrealized Losses | Fair Value | Investments | Other Assets | |||||||||||||||||||||||||||||
| Level 1: | |||||||||||||||||||||||||||||||||||
| U.S. government and agency securities | $ | 491 | $ | — | $ | (11) | $ | 481 | $ | 481 | $ | — | |||||||||||||||||||||||
| Level 2: | |||||||||||||||||||||||||||||||||||
| Corporate debt securities | 3,444 | 7 | (54) | 3,397 | 3,397 | — | |||||||||||||||||||||||||||||
| U.S. government and agency securities | 912 | — | (27) | 885 | 885 | — | |||||||||||||||||||||||||||||
| Mortgage-backed securities | 868 | 3 | (36) | 835 | 835 | — | |||||||||||||||||||||||||||||
| Non-U.S. government and agency securities | 6 | — | — | 6 | 6 | — | |||||||||||||||||||||||||||||
| Other asset-backed securities | 1,058 | 5 | (4) | 1,059 | 1,059 | — | |||||||||||||||||||||||||||||
| Total Level 2 | 6,288 | 15 | (121) | 6,182 | 6,182 | — | |||||||||||||||||||||||||||||
| Level 3: | |||||||||||||||||||||||||||||||||||
| Auction rate securities | 36 | — | (3) | 33 | — | 33 | |||||||||||||||||||||||||||||
| Total available-for-sale debt securities | $ | 6,815 | $ | 15 | $ | (134) | $ | 6,696 | $ | 6,663 | $ | 33 |
| April 26, 2024 | |||||||||||||||||||||||||||||||||||
| Valuation | Balance Sheet Classification | ||||||||||||||||||||||||||||||||||
| (in millions) | Cost | Unrealized Gains | Unrealized Losses | Fair Value | Investments | Other Assets | |||||||||||||||||||||||||||||
| Level 1: | |||||||||||||||||||||||||||||||||||
| U.S. government and agency securities | $ | 494 | $ | — | $ | (22) | $ | 472 | $ | 472 | $ | — | |||||||||||||||||||||||
| Level 2: | |||||||||||||||||||||||||||||||||||
| Corporate debt securities | 3,953 | 4 | (125) | 3,832 | 3,832 | — | |||||||||||||||||||||||||||||
| U.S. government and agency securities | 847 | — | (43) | 804 | 804 | — | |||||||||||||||||||||||||||||
| Mortgage-backed securities | 692 | 1 | (50) | 643 | 643 | — | |||||||||||||||||||||||||||||
| Non-U.S. government and agency securities | 5 | — | — | 5 | 5 | — | |||||||||||||||||||||||||||||
| Other asset-backed securities | 941 | 2 | (9) | 934 | 934 | — | |||||||||||||||||||||||||||||
| Total Level 2 | 6,438 | 7 | (227) | 6,218 | 6,218 | — | |||||||||||||||||||||||||||||
| Level 3: | |||||||||||||||||||||||||||||||||||
| Auction rate securities | 36 | — | (3) | 33 | — | 33 | |||||||||||||||||||||||||||||
| Total available-for-sale debt securities | $ | 6,968 | $ | 7 | $ | (252) | $ | 6,723 | $ | 6,690 | $ | 33 |
The amortized cost of debt securities excludes accrued interest, which is reported in other current assets in the consolidated balance sheets.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at January 24, 2025 and April 26, 2024:
| January 24, 2025 | |||||||||||||||||||||||
| Less than 12 months | More than 12 months | ||||||||||||||||||||||
| (in millions) | Fair Value | Unrealized Losses | Fair Value | Unrealized Losses | |||||||||||||||||||
| Corporate debt securities | $ | 672 | $ | (7) | $ | 1,691 | $ | (47) | |||||||||||||||
| U.S. government and agency securities | 180 | (2) | 692 | (35) | |||||||||||||||||||
| Mortgage-backed securities | — | — | 631 | (36) | |||||||||||||||||||
| Other asset-backed securities | — | — | 252 | (4) | |||||||||||||||||||
| Auction rate securities | — | — | 33 | (3) | |||||||||||||||||||
| Total | $ | 852 | $ | (9) | $ | 3,299 | $ | (125) |
| April 26, 2024 | |||||||||||||||||||||||
| Less than 12 months | More than 12 months | ||||||||||||||||||||||
| (in millions) | Fair Value | Unrealized Losses | Fair Value | Unrealized Losses | |||||||||||||||||||
| Corporate debt securities | $ | 661 | $ | (10) | $ | 2,448 | $ | (116) | |||||||||||||||
| U.S. government and agency securities | 177 | (4) | 730 | (61) | |||||||||||||||||||
| Mortgage-backed securities | — | — | 582 | (50) | |||||||||||||||||||
| Other asset-backed securities | — | — | 502 | (9) | |||||||||||||||||||
| Auction rate securities | — | — | 33 | (3) | |||||||||||||||||||
| Total | $ | 838 | $ | (14) | $ | 4,296 | $ | (238) |
The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the three and nine months ended January 24, 2025 and January 26, 2024. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement.
Activity related to the Company’s available-for-sale debt securities portfolio is as follows:
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||
| Proceeds from sales | $ | 1,890 | $ | 1,794 | $ | 6,134 | $ | 5,114 | |||||||||||||||
| Gross realized gains | 5 | 7 | 19 | 18 | |||||||||||||||||||
| Gross realized losses | (3) | (6) | (16) | (22) | |||||||||||||||||||
The contractual maturities of available-for-sale debt securities at January 24, 2025 is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.
| (in millions) | Amortized Cost | Fair Value | |||||||||
| Due in one year or less | $ | 1,560 | $ | 1,551 | |||||||
| Due after one year through five years | 3,257 | 3,185 | |||||||||
| Due after five years through ten years | 784 | 778 | |||||||||
| Due after ten years | 1,215 | 1,183 | |||||||||
| Total | $ | 6,815 | $ | 6,696 |
Interest income, which includes income on marketable debt securities and the global liquidity structure, is recognized in other non-operating income, net, in the consolidated statements of income. During the three and nine months ended January 24, 2025, there were $114 million and $364 million of interest income, respectively. During the three and nine months ended January 26, 2024, there was $170 million and $429 million of interest income, respectively.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
Equity Securities, Equity Method Investments, and Other Investments
The Company holds investments in equity securities with readily determinable fair values, equity method investments for which the Company has elected the fair value option, equity investments without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity securities with readily determinable fair values are included in Level 1 of the fair value hierarchy, as they are measured using quoted market prices. Equity method investments for which the Company has elected the fair value option are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses a discounted cash flow methodology, taking into consideration various assumptions including discount rate, and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values, and that are not accounted for via the fair value option, are included within Level 3 of the fair value hierarchy, as they are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer.
The following table summarizes the Company's equity and other investments at January 24, 2025 and April 26, 2024, which are classified as primarily other assets in the consolidated balance sheets:
| (in millions) | January 24, 2025 | April 26, 2024 | ||||||||||||
| Investments with readily determinable fair value (marketable equity securities) | $ | 32 | $ | 28 | ||||||||||
| Investments for which the fair value option has been elected | 311 | 311 | ||||||||||||
| Investments without readily determinable fair values | 809 | 859 | ||||||||||||
| Equity method and other investments | 77 | 84 | ||||||||||||
| Total equity and other investments | $ | 1,230 | $ | 1,282 |
The table below includes activity related to the Company's portfolio of equity and other investments. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income.
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||
| Proceeds from sales | $ | 27 | $ | 12 | $ | 120 | $ | 28 | |||||||||||||||
| Gross gains | 8 | 33 | 100 | 31 | |||||||||||||||||||
| Gross losses | (4) | (38) | (17) | (111) | |||||||||||||||||||
| Impairment losses recognized | (71) | — | (116) | (21) |
During the three and nine months ended January 24, 2025, there were $2 million of net unrealized losses and $5 million of net unrealized gains, respectively, on equity securities and other investments still held at January 24, 2025. During the three and nine months ended January 26, 2024, there were $25 million and $95 million of net unrealized losses, respectively, on equity securities and other investments still held at January 26, 2024.
Mozarc Medical Investment
As further described in Note 4, on April 1, 2023, the Company sold half of its RCS business to Mozarc, and as a result of the transaction the Company retained a 50 percent equity interest in Mozarc. Although the equity investment provides the Company with the ability to exercise significant influence over Mozarc, the Company has elected the fair value option to account for this equity investment. The Company believes the fair value option best reflects the economics of the underlying transaction.
Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period in other non-operating income, net in the consolidated statements of income. During the three and nine months ended January 24, 2025, the change in fair value was not significant. During the three and nine months ended January 26, 2024, the Company recognized a loss of $39 million.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
7. Financing Arrangements
Commercial Paper
The Company maintains commercial paper programs that allow the Company to issue U.S. dollar or Euro-denominated unsecured commercial paper notes. The aggregate amount outstanding at any time under the commercial paper programs may not exceed the equivalent of $3.5 billion. There was no commercial paper outstanding at January 24, 2025. During the three and nine months ended January 24, 2025, the commercial paper outstanding had a weighted average original maturity of 13 days and 14 days, respectively, and a weighted average interest rate of 4.66 percent and 5.12 percent, respectively. Commercial paper outstanding at April 26, 2024 was $1.1 billion. During fiscal year 2024, the weighted average original maturity of the commercial paper outstanding was approximately 20 days and the weighted average interest rate was 5.45 percent. The issuance of commercial paper reduces the amount of credit available under the Company’s existing Credit Facility, as defined below.
Line of Credit
The Company has a $3.5 billion five-year unsecured revolving credit facility (Credit Facility), which provides back-up funding for the commercial paper programs described above. The Credit Facility includes a multi-currency borrowing feature for certain specified foreign currencies. At January 24, 2025 and April 26, 2024, no amounts were outstanding under the Credit Facility.
Interest rates on advances on the Credit Facility are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Company is in compliance with the covenants under the Credit Facility.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
Debt Obligations
The Company's debt obligations consisted of the following:
| (in millions) | Maturity by Fiscal Year | January 24, 2025 | April 26, 2024 | |||||||||||||||||
| Current debt obligations | 2025 - 2026 | $ | 2,622 | $ | 1,092 | |||||||||||||||
| Long-term debt | ||||||||||||||||||||
| 0.250 percent six-year 2019 senior notes | 2026 | — | 1,070 | |||||||||||||||||
| 2.625 percent three-year 2022 senior notes | 2026 | — | 535 | |||||||||||||||||
| 0.000 percent five-year 2020 senior notes | 2026 | — | 1,070 | |||||||||||||||||
| 1.125 percent eight-year 2019 senior notes | 2027 | 1,563 | 1,606 | |||||||||||||||||
| 4.250 percent five-year 2023 senior notes | 2028 | 1,000 | 1,000 | |||||||||||||||||
| 3.000 percent six-year 2022 senior notes | 2029 | 1,042 | 1,070 | |||||||||||||||||
| 0.375 percent eight-year 2020 senior notes | 2029 | 1,042 | 1,070 | |||||||||||||||||
| 3.650 percent five-year 2024 senior notes | 2030 | 886 | — | |||||||||||||||||
| 1.625 percent twelve-year 2019 senior notes | 2031 | 1,042 | 1,070 | |||||||||||||||||
| 1.000 percent twelve-year 2019 senior notes | 2032 | 1,042 | 1,070 | |||||||||||||||||
| 3.125 percent nine-year 2022 senior notes | 2032 | 1,042 | 1,070 | |||||||||||||||||
| 0.750 percent twelve-year 2020 senior notes | 2033 | 1,042 | 1,070 | |||||||||||||||||
| 4.500 percent ten-year 2023 senior notes | 2033 | 1,000 | 1,000 | |||||||||||||||||
| 3.375 percent twelve-year 2022 senior notes | 2035 | 1,042 | 1,070 | |||||||||||||||||
| 4.375 percent twenty-year 2015 senior notes | 2035 | 1,932 | 1,932 | |||||||||||||||||
| 3.875 percent twelve-year 2024 senior notes | 2037 | 886 | — | |||||||||||||||||
| 6.550 percent thirty-year 2007 CIFSA senior notes | 2038 | 253 | 253 | |||||||||||||||||
| 2.250 percent twenty-year 2019 senior notes | 2039 | 1,042 | 1,070 | |||||||||||||||||
| 6.500 percent thirty-year 2009 senior notes | 2039 | 158 | 158 | |||||||||||||||||
| 1.500 percent twenty-year 2019 senior notes | 2040 | 1,042 | 1,070 | |||||||||||||||||
| 5.550 percent thirty-year 2010 senior notes | 2040 | 224 | 224 | |||||||||||||||||
| 1.375 percent twenty-year 2020 senior notes | 2041 | 1,042 | 1,070 | |||||||||||||||||
| 4.500 percent thirty-year 2012 senior notes | 2042 | 105 | 105 | |||||||||||||||||
| 4.000 percent thirty-year 2013 senior notes | 2043 | 305 | 305 | |||||||||||||||||
| 4.150 percent nineteen-year 2024 senior notes | 2044 | 625 | — | |||||||||||||||||
| 4.625 percent thirty-year 2014 senior notes | 2044 | 127 | 127 | |||||||||||||||||
| 4.625 percent thirty-year 2015 senior notes | 2045 | 1,813 | 1,813 | |||||||||||||||||
| 1.750 percent thirty-year 2019 senior notes | 2050 | 1,042 | 1,070 | |||||||||||||||||
| 1.625 percent thirty-year 2020 senior notes | 2051 | 1,042 | 1,070 | |||||||||||||||||
| 4.150 percent twenty-nine-year 2024 senior notes | 2054 | 729 | — | |||||||||||||||||
| Finance lease obligations | 2026 - 2040 | 50 | 55 | |||||||||||||||||
| Deferred financing costs | 2027 - 2054 | (121) | (110) | |||||||||||||||||
| Debt discount, net | 2027 - 2054 | (51) | (55) | |||||||||||||||||
| Total long-term debt | $ | 23,985 | $ | 23,932 |
Interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums, and the global liquidity structure is recognized in interest expense, net in the consolidated statements of income. During the three and nine months ended January 24, 2025, there was $224 million and $693 million, respectively, of interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums, and the global liquidity structure. During the three and nine months ended January 26, 2024, there was $237 million and $664 million, respectively, of interest expense on outstanding borrowings, including
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
amortization of debt issuance costs and debt discounts and premiums, and the global liquidity structure.
Senior Notes
The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The Company is in compliance with all covenants related to the Senior Notes.
On June 3, 2024, Medtronic Inc. issued four tranches of EUR-denominated Senior Notes with an aggregate principal of €3.0 billion, with maturities ranging from fiscal year 2030 to 2054, resulting in cash proceeds of approximately $3.2 billion, net of discounts and issuance costs. In anticipation of the Euro-denominated debt issuance, the Company entered into forward currency exchange rate contracts to manage the exposure to exchange rate movements. These contracts were settled in conjunction with the issuance of the June 2024 Notes.
Financial Instruments Not Measured at Fair Value
At January 24, 2025, the estimated fair value of the Company’s Senior Notes was $24.4 billion compared to a principal value of $26.7 billion. At April 26, 2024, the estimated fair value was $21.2 billion compared to a principal value of $24.0 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.
8. Derivatives and Currency Exchange Risk Management
The Company uses derivative instruments and foreign currency denominated debt to manage the impact that currency exchange rate and interest rate changes have on reported financial statements. The Company does not enter into derivative contracts for speculative purposes.
Fair Value Hedges
Beginning in the first quarter of fiscal year 2025, the Company began using foreign currency forward contracts designated as fair value hedges to manage its exposure to changes in the fair value of its fixed-rate debt obligation.
At inception, foreign currency forward contracts are designated as fair value hedges. Changes in the fair value of these derivatives are reported as a component of other operating (income) expense, net. Amounts excluded from the assessment of effectiveness are recognized in interest expense, net on a straight-line basis over the term of the hedge. During the three and nine months ended January 24, 2025, amounts related to excluded components that are amortized in interest expense, net over the life of the hedging instrument were not significant. Cash flows related to the Company's derivative instruments designated as fair value hedges are reported as financing activities in the consolidated statements of cash flows. Cash flows attributed to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.
Cash Flow Hedges
The Company uses foreign currency forward and option contracts designated as cash flow hedges to manage its exposure to the variability of future cash flows that are denominated in a foreign currency.
At inception, foreign currency forward and option contracts are designated as cash flow hedges. Changes in the fair value of these derivatives are reported as a component of accumulated other comprehensive loss until the hedged transaction affects earnings. When the hedged transaction affects earnings, the gain or loss on the derivative is reclassified to earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings on a straight-line basis over the term of the hedge. Cash flows are reported as operating activities in the consolidated statements of cash flows.
The Company's cash flow hedges will mature within the subsequent three-year period. At January 24, 2025 and April 26, 2024, the Company had $432 million and $229 million in after-tax unrealized gains, respectively, associated with cash flow hedging instruments recorded in accumulated other comprehensive loss. The Company expects that $289 million of after-tax net unrealized gains at January 24, 2025 will be recognized in the consolidated statements of income over the next 12 months.
Net Investment Hedges
The Company uses derivative instruments and foreign currency denominated debt to manage foreign currency risk associated with its net investment in foreign operations. The derivative instruments that the Company uses for this purpose may include foreign currency forward exchange contracts used on a standalone basis or in combination with option collars and standalone cross currency interest rate contracts.
For instruments that are designated as net investment hedges, the gains or losses are reported as a component of accumulated other comprehensive loss. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
Amounts excluded from the assessment of effectiveness are recognized in interest expense, net on a straight-line basis over the term of the hedge. During the three and nine months ended January 24, 2025, the Company recognized $50 million and $148 million, respectively, in after-tax unrealized gains representing excluded components in interest expense, net. During the three and nine months ended January 26, 2024, the Company recognized $49 million and $148 million, respectively, in after-tax unrealized gains representing excluded components in interest expense, net. The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. Cash flows attributable to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.
Undesignated Derivatives
The Company uses foreign currency forward exchange contracts to offset the Company’s exposure to the change in the value of non-functional currency denominated assets, liabilities, and cash flows.
These foreign currency forward exchange rate contracts are not designated as hedges at inception, and therefore, changes in the fair value of these contracts are recognized in the consolidated statements of income. Cash flows related to the Company’s undesignated derivative contracts are reported in the consolidated statements of cash flows based on the nature of the derivative instrument.
Outstanding Instruments
The following table presents the contractual amounts of the Company's outstanding instruments:
| As of | |||||||||||||||||
| (in billions) | Designation | January 24, 2025 | April 26, 2024 | ||||||||||||||
| Currency exchange rate contracts(1) | Fair value hedge | $ | 1.0 | $ | — | ||||||||||||
| Currency exchange rate contracts | Cash flow hedge | 9.9 | 10.4 | ||||||||||||||
| Currency exchange rate contracts(2) | Net investment hedge | 8.3 | 7.4 | ||||||||||||||
| Foreign currency-denominated debt(3) | Net investment hedge | 18.8 | 17.1 | ||||||||||||||
| Currency exchange rate contracts | Undesignated | 4.6 | 5.9 |
(1)At January 24, 2025, includes derivative contracts with a notional value of €1.0 billion, or $1.0 billion, designated as hedges of a portion of our fixed-rate debt obligations.
(2)At January 24, 2025, includes derivative contracts with a notional value of €6.0 billion, or $6.3 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of ¥322.2 billion, or $2.1 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2025 through 2033.
(3)At January 24, 2025, includes €18.0 billion, or $18.8 billion, of outstanding Euro-denominated debt designated as hedges of a portion of our net investment in foreign operations. This debt matures in fiscal years 2026 through 2054.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
Gains and Losses on Hedging Instruments and Derivatives not Designated as Hedging Instruments
The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for the three and nine months ended January 24, 2025 and January 26, 2024 were as follows:
| (Gain) Loss Recognized in Accumulated Other Comprehensive Loss | (Gain) Loss Reclassified into Income | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Three months ended | Nine months ended | Three months ended | Nine months ended | Location of (Gain) Loss in Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||||||||||||||||||||||||||||
| Fair value hedges | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Currency exchange rate contracts | $ | — | $ | — | $ | (1) | $ | — | $ | 38 | $ | — | $ | 42 | $ | — | Other operating (income) expense, net | ||||||||||||||||||||||||||||||||||||
| Cash flow hedges | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Currency exchange rate contracts | (346) | 136 | (303) | (263) | (49) | (83) | (88) | (209) | Other operating (income) expense, net | ||||||||||||||||||||||||||||||||||||||||||||
| Currency exchange rate contracts | (55) | 23 | (55) | (85) | (17) | (20) | (56) | (39) | Cost of products sold | ||||||||||||||||||||||||||||||||||||||||||||
| Net investment hedges | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency-denominated debt | (684) | 406 | (525) | (206) | — | — | — | — | N/A | ||||||||||||||||||||||||||||||||||||||||||||
| Currency exchange rate contracts | (124) | 18 | (112) | (142) | — | — | — | — | N/A | ||||||||||||||||||||||||||||||||||||||||||||
| Total | $ | (1,209) | $ | 584 | $ | (996) | $ | (696) | $ | (28) | $ | (103) | $ | (102) | $ | (248) |
The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements during the three and nine months ended January 24, 2025 and January 26, 2024 were as follows:
| (Gain) Loss Recognized in Income | |||||||||||||||||||||||||||||
| Three months ended | Nine months ended | Location of (Gain) Loss in Income Statement | |||||||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||||||||
| Currency exchange rate contracts | $ | 65 | $ | (9) | $ | 60 | $ | 83 | Other operating (income) expense, net | ||||||||||||||||||||
Balance Sheet Presentation
The following table summarizes the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at January 24, 2025 and April 26, 2024. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.
| Fair Value - Assets | Fair Value - Liabilities | ||||||||||||||||||||||||||||||||||
| (in millions) | January 24, 2025 | April 26, 2024 | Balance Sheet Classification | January 24, 2025 | April 26, 2024 | Balance Sheet Classification | |||||||||||||||||||||||||||||
| Derivatives designated as hedging instruments | |||||||||||||||||||||||||||||||||||
| Currency exchange rate contracts | $ | 515 | $ | 368 | Other current assets | $ | 57 | $ | 37 | Other accrued expenses | |||||||||||||||||||||||||
| Currency exchange rate contracts | 416 | 276 | Other assets | 2 | 17 | Other liabilities | |||||||||||||||||||||||||||||
| Total derivatives designated as hedging instruments | 932 | 644 | 59 | 54 | |||||||||||||||||||||||||||||||
| Derivatives not designated as hedging instruments | |||||||||||||||||||||||||||||||||||
| Currency exchange rate contracts | 39 | 15 | Other current assets | 20 | 12 | Other accrued expenses | |||||||||||||||||||||||||||||
| Total return swaps | 9 | — | Other current assets | — | — | Other accrued expenses | |||||||||||||||||||||||||||||
| Total derivatives not designated as hedging instruments | 48 | 15 | 20 | 12 | |||||||||||||||||||||||||||||||
| Total derivatives | $ | 980 | $ | 659 | $ | 79 | $ | 66 |
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis.
| January 24, 2025 | April 26, 2024 | ||||||||||||||||||||||||||||||||||
| (in millions) | Derivative Assets | Derivative Liabilities | Derivative Assets | Derivative Liabilities | |||||||||||||||||||||||||||||||
| Level 1 | $ | 971 | $ | 79 | $ | 659 | $ | 66 | |||||||||||||||||||||||||||
| Level 2 | 9 | — | — | — | |||||||||||||||||||||||||||||||
| Total | $ | 980 | $ | 79 | $ | 659 | $ | 66 |
The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows.
The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.
| January 24, 2025 | ||||||||||||||||||||||||||||||||
| Gross Amount Not Offset on the Balance Sheet | ||||||||||||||||||||||||||||||||
| (in millions) | Gross Amount of Recognized Assets (Liabilities) | Financial Instruments | Cash Collateral (Received) Posted | Net Amount | ||||||||||||||||||||||||||||
| Derivative assets: | ||||||||||||||||||||||||||||||||
| Currency exchange rate contracts | $ | 971 | $ | (79) | $ | (271) | $ | 620 | ||||||||||||||||||||||||
| Total return swaps | 9 | — | — | 9 | ||||||||||||||||||||||||||||
| 980 | (79) | (271) | 629 | |||||||||||||||||||||||||||||
| Derivative liabilities: | ||||||||||||||||||||||||||||||||
| Currency exchange rate contracts | (79) | 79 | — | — | ||||||||||||||||||||||||||||
| Total | $ | 901 | $ | — | $ | (271) | $ | 629 |
| April 26, 2024 | ||||||||||||||||||||||||||||||||||||||
| Gross Amount Not Offset on the Balance Sheet | ||||||||||||||||||||||||||||||||||||||
| (in millions) | Gross Amount of Recognized Assets (Liabilities) | Financial Instruments | Cash Collateral (Received) Posted | Net Amount | ||||||||||||||||||||||||||||||||||
| Derivative assets: | ||||||||||||||||||||||||||||||||||||||
| Currency exchange rate contracts | $ | 659 | $ | (66) | $ | (101) | $ | 492 | ||||||||||||||||||||||||||||||
| Derivative liabilities: | ||||||||||||||||||||||||||||||||||||||
| Currency exchange rate contracts | (66) | 66 | — | — | ||||||||||||||||||||||||||||||||||
| Total | $ | 593 | $ | — | $ | (101) | $ | 492 |
9. Inventories
Inventory balances were as follows:
| (in millions) | January 24, 2025 | April 26, 2024 | |||||||||
| Finished goods | $ | 3,740 | $ | 3,668 | |||||||
| Work-in-process | 782 | 642 | |||||||||
| Raw materials | 1,089 | 907 | |||||||||
| Total | $ | 5,610 | $ | 5,217 |
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
10. Goodwill and Other Intangible Assets
Goodwill
The following table presents the changes in the carrying amount of goodwill by segment:
| (in millions) | Cardiovascular | Neuroscience | Medical Surgical | Diabetes | Total | ||||||||||||||||||||||||
| April 26, 2024 | $ | 7,966 | $ | 11,644 | $ | 19,121 | $ | 2,255 | $ | 40,986 | |||||||||||||||||||
| Goodwill as a result of acquisitions | — | — | 108 | — | 108 | ||||||||||||||||||||||||
| Purchase accounting adjustments | 2 | — | — | — | 2 | ||||||||||||||||||||||||
| Currency translation and other | (38) | (34) | (204) | — | (277) | ||||||||||||||||||||||||
| January 24, 2025 | $ | 7,929 | $ | 11,611 | $ | 19,025 | $ | 2,254 | $ | 40,819 |
As further described in Note 17, the Company had changes to the operating segments and goodwill reporting units during the fourth quarter of fiscal year 2024. For further information on the reporting unit changes, refer to Note 9 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024.
The Company assesses goodwill for impairment annually as of the first day of the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting unit level. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and revenue and earnings multiples using comparable public company information. Significant assumptions used in reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit. A change in any of these estimates and assumptions could produce a different fair value, which could have a material impact on the Company's results of operations. No goodwill impairment was recognized during the three and nine months ended January 24, 2025 and January 26, 2024.
The following table presents the gross carrying amount and accumulated amortization of intangible assets:
| January 24, 2025 | April 26, 2024 | ||||||||||||||||||||||
| (in millions) | Gross Carrying Amount | Accumulated Amortization | Gross Carrying Amount | Accumulated Amortization | |||||||||||||||||||
| Definite-lived: | |||||||||||||||||||||||
| Customer-related | $ | 16,509 | $ | (9,391) | $ | 16,518 | $ | (8,689) | |||||||||||||||
| Purchased technology and patents | 11,751 | (7,369) | 11,557 | (6,868) | |||||||||||||||||||
| Trademarks and tradenames | 423 | (281) | 424 | (274) | |||||||||||||||||||
| Other | 353 | (94) | 256 | (84) | |||||||||||||||||||
| Total | $ | 29,036 | $ | (17,136) | $ | 28,755 | $ | (15,915) | |||||||||||||||
| Indefinite-lived: | |||||||||||||||||||||||
| IPR&D | $ | 284 | $ | — | $ | 385 | $ | — | |||||||||||||||
The Company did not recognize any definite-lived intangible asset impairment charges during the three and nine months ended January 24, 2025 and January 26, 2024.
The Company did not recognize any indefinite-lived intangible asset impairment charges during the three months ended January 24, 2025 and January 26, 2024, and during the nine months ended January 24, 2025. Indefinite-lived intangible asset impairment charges were not significant for the nine months ended January 26, 2024. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
Amortization Expense
Intangible asset amortization expense for the three months ended January 24, 2025 and January 26, 2024 was $416 million and $419 million, respectively. Intangible asset amortization expense for the nine months ended January 24, 2025 and January 26, 2024 was $1.2 billion and $1.3 billion, respectively. Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at January 24, 2025, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows:
| (in millions) | Amortization Expense | ||||
| Remaining 2025 | $ | 414 | |||
| 2026 | 1,648 | ||||
| 2027 | 1,625 | ||||
| 2028 | 1,574 | ||||
| 2029 | 1,498 | ||||
| 2030 | 1,365 | ||||
11. Income Taxes
The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. The OECD has since issued administrative guidance providing transition and safe harbor rules around the implementation of the Pillar Two global minimum tax. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two, which are effective for the Company in fiscal year 2025. We will continue to monitor the impacts of further legislation, regulatory guidance, and regulations issued in the countries in which we do business.
The Israeli Central-Lod District Court issued its decision in the Medtronic Ventor Technologies Ltd (Ventor) v. Kfar Saba Assessing Office on June 1, 2023. The court determined that there was a deemed taxable transfer of intellectual property. As a result, the Company recorded a $187 million income tax charge during the first quarter of fiscal year 2024 and has filed an appeal with the Supreme Court of Israel.
The Company's effective tax rate for the three and nine months ended January 24, 2025 was 15.4% and 16.9%, respectively, as compared to 9.2% and 23.5% for the three and nine months ended January 26, 2024, respectively. The increase in the effective tax rate for the three months ended January 24, 2025 primarily relates to a Swiss Cantonal tax rate change on previously recorded deferred tax assets during the three months ended January 26, 2024, and the implementation of the Pillar Two global minimum tax. The decrease in the effective tax rate for the nine months ended January 24, 2025 was primarily attributable to the establishment of a valuation allowance on certain net operating losses and an income tax reserve adjustment made during the nine months ended January 26, 2024 associated with the Ventor court decision noted above, which was partially offset by the Swiss Cantonal tax rate change on previously recorded deferred tax assets and the implementation of the Pillar Two global minimum tax noted above.
At January 24, 2025 and April 26, 2024, the Company's gross unrecognized tax benefits were $2.9 billion and $2.8 billion, respectively. In addition, the Company had accrued gross interest and penalties of $63 million at January 24, 2025. If all of the Company’s unrecognized tax benefits were recognized, approximately $2.7 billion would impact the Company’s effective tax rate. At January 24, 2025 and April 26, 2024, the amount of the Company's gross unrecognized tax benefits, net of cash advance, recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheets was $1.9 billion and $1.8 billion, respectively. The Company recognizes interest and penalties related to income tax matters within income tax provision in the consolidated statements of income and records the liability within either current or noncurrent accrued income taxes on the consolidated balance sheets.
Refer to Note 16 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.
12. Earnings Per Share
Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
The table below sets forth the computation of basic and diluted earnings per share:
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions, except per share data) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||
| Numerator: | |||||||||||||||||||||||
| Net income attributable to ordinary shareholders | $ | 1,294 | $ | 1,322 | $ | 3,606 | $ | 3,022 | |||||||||||||||
| Denominator: | |||||||||||||||||||||||
| Basic – weighted average shares outstanding | 1,282.4 | 1,329.7 | 1,286.7 | 1,330.1 | |||||||||||||||||||
| Effect of dilutive securities: | |||||||||||||||||||||||
| Employee stock options | 0.5 | 0.4 | 0.5 | 0.7 | |||||||||||||||||||
| Employee restricted stock units | 2.1 | 1.1 | 2.1 | 1.2 | |||||||||||||||||||
| Employee performance share units | 1.3 | 0.4 | 1.3 | 0.3 | |||||||||||||||||||
| Diluted – weighted average shares outstanding | 1,286.2 | 1,331.7 | 1,290.6 | 1,332.4 | |||||||||||||||||||
| Basic earnings per share | $ | 1.01 | $ | 0.99 | $ | 2.80 | $ | 2.27 | |||||||||||||||
| Diluted earnings per share | $ | 1.01 | $ | 0.99 | $ | 2.79 | $ | 2.27 |
The calculation of weighted average diluted shares outstanding excludes options to purchase approximately 26 million and 27 million ordinary shares for the three and nine months ended January 24, 2025, respectively, and 29 million and 28 million ordinary shares for the three and nine months ended January 26, 2024, respectively, because their effect would have been anti-dilutive on the Company’s earnings per share.
13. Stock-Based Compensation
The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, performance share units, and employee stock purchase plan shares recognized for the three and nine months ended January 24, 2025 and January 26, 2024:
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||
| Stock options | $ | 13 | $ | 15 | $ | 55 | $ | 61 | |||||||||||||||
| Restricted stock | 54 | 45 | 165 | 138 | |||||||||||||||||||
| Performance share units | 23 | 18 | 93 | 78 | |||||||||||||||||||
| Employee stock purchase plan | 7 | 8 | 26 | 27 | |||||||||||||||||||
| Total stock-based compensation expense | $ | 98 | $ | 85 | $ | 340 | $ | 303 | |||||||||||||||
| Cost of products sold | $ | 11 | $ | 8 | $ | 37 | $ | 27 | |||||||||||||||
| Research and development expense | 12 | 10 | 41 | 36 | |||||||||||||||||||
| Selling, general, and administrative expense | 75 | 67 | 262 | 240 | |||||||||||||||||||
| Total stock-based compensation expense | 98 | 85 | 340 | 303 | |||||||||||||||||||
| Income tax benefits | (17) | (14) | (55) | (50) | |||||||||||||||||||
| Total stock-based compensation expense, net of tax | $ | 81 | $ | 70 | $ | 285 | $ | 253 |
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
14. Retirement Benefit Plans
The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three and nine months ended January 24, 2025 and January 26, 2024:
| U.S. | Non-U.S. | U.S. | Non-U.S. | ||||||||||||||||||||||||||||||||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||||||||||||||||||||||
| Service cost | $ | 13 | $ | 15 | $ | 11 | $ | 10 | $ | 39 | $ | 45 | $ | 33 | $ | 30 | |||||||||||||||||||||||||||||||
| Interest cost | 43 | 40 | 13 | 12 | 129 | 120 | 39 | 36 | |||||||||||||||||||||||||||||||||||||||
| Expected return on plan assets | (66) | (65) | (17) | (17) | (198) | (195) | (51) | (51) | |||||||||||||||||||||||||||||||||||||||
| Amortization of prior service cost | (1) | (1) | — | — | (3) | (3) | — | — | |||||||||||||||||||||||||||||||||||||||
| Amortization of net actuarial loss | 4 | 5 | — | — | 12 | 15 | 1 | — | |||||||||||||||||||||||||||||||||||||||
| Net periodic (credit) benefit cost | $ | (7) | $ | (6) | $ | 7 | $ | 5 | $ | (21) | $ | (18) | $ | 22 | $ | 15 | |||||||||||||||||||||||||||||||
Components of net periodic (credit) benefit cost other than the service component are recognized in other non-operating income, net in the consolidated statements of income.
15. Accumulated Other Comprehensive Loss
The following table provides changes in accumulated other comprehensive loss (AOCI), net of tax, and by component:
| (in millions) | Unrealized (Loss) Gain on Investment Securities | Cumulative Translation Adjustments | Net Investment Hedges | Net Change in Retirement Obligations | Unrealized Gain (Loss) on Cash Flow Hedges | Total Accumulated Other Comprehensive (Loss) Income | |||||||||||||||||||||||||||||
| April 26, 2024 | $ | (212) | $ | (3,686) | $ | 878 | $ | (529) | $ | 229 | $ | (3,318) | |||||||||||||||||||||||
| Other comprehensive income (loss) before reclassifications | 98 | (443) | 610 | (1) | 307 | 570 | |||||||||||||||||||||||||||||
| Reclassifications | 12 | — | — | 4 | (107) | (91) | |||||||||||||||||||||||||||||
| Other comprehensive income (loss) | 110 | (443) | 610 | 3 | 200 | 479 | |||||||||||||||||||||||||||||
| January 24, 2025 | $ | (102) | $ | (4,129) | $ | 1,488 | $ | (527) | $ | 432 | $ | (2,839) | |||||||||||||||||||||||
| (in millions) | Unrealized (Loss) Gain on Investment Securities | Cumulative Translation Adjustments | Net Investment Hedges | Net Change in Retirement Obligations | Unrealized Gain (Loss) on Cash Flow Hedges | Total Accumulated Other Comprehensive (Loss) Income | |||||||||||||||||||||||||||||
| April 28, 2023 | $ | (258) | $ | (2,839) | $ | 245 | $ | (741) | $ | 93 | $ | (3,499) | |||||||||||||||||||||||
| Other comprehensive income (loss) before reclassifications | 59 | (461) | 348 | 1 | 273 | 219 | |||||||||||||||||||||||||||||
| Reclassifications | 14 | — | — | 6 | (200) | (180) | |||||||||||||||||||||||||||||
| Other comprehensive income (loss) | 73 | (461) | 348 | 6 | 74 | 39 | |||||||||||||||||||||||||||||
| January 26, 2024 | $ | (185) | $ | (3,300) | $ | 593 | $ | (735) | $ | 167 | $ | (3,459) |
The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during the nine months ended January 24, 2025 and January 26, 2024, was an expense of $19 million and $9 million, respectively. During the nine months ended January 24, 2025 and January 26, 2024, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $2 million and $4 million, respectively. When realized, gains and losses on investment securities reclassified from AOCI are recognized within other non-operating income, net. Refer to Note 6 to the consolidated financial statements for additional information.
During the nine months ended January 24, 2025, the income tax on cumulative translation adjustments was a benefit of $3 million. During the nine months ended January 26, 2024, there was no income tax on cumulative translation adjustments.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
The income tax on net investment hedges in other comprehensive income before reclassifications during the nine months ended January 24, 2025 was an expense of $28 million. During the nine months ended January 26, 2024, there were no tax impacts on net investment hedges. Refer to Note 8 to the consolidated financial statements for additional information.
The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. During the nine months ended January 24, 2025 and January 26, 2024, there were no tax impacts on retirement obligations. During the nine months ended January 24, 2025 and January 26, 2024, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of $2 million. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within other non-operating income, net. Refer to Note 14 to the consolidated financial statements for additional information.
The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during the nine months ended January 24, 2025 and January 26, 2024, was an expense of $51 million and $75 million, respectively. During the nine months ended January 24, 2025 and January 26, 2024, gains and losses on cash flow hedges reclassified from AOCI were reduced by income taxes of $36 million and $48 million, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within other operating (income) expense, net or cost of products sold. Refer to Note 8 to the consolidated financial statements for additional information.
16. Commitments and Contingencies
Legal Matters
The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. With respect to intellectual property disputes, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements relating to such rights. This litigation includes, but is not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or, consistent with a growing trend across technology-intensive industries, other entities created specifically to fund IP litigation. With respect to commercial disputes, antitrust and competition issues have gained increased prominence, enforcement and private litigation have increased globally, and the Company is involved in or at risk for antitrust litigation, investigations or enforcement actions regarding a range of commercial activities, including challenges to mergers and acquisition transactions, joint ventures, co-development or co-marketing arrangements, contracting practices, distribution agreements and employment agreements. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek significant monetary damages and/or royalty payments, as well as other civil or criminal remedies (including injunctions barring or restricting the sale of products that are the subject of the proceeding, placing restrictions on competitive strategies or practices, or unwinding consummated transactions), any or all of which could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.
The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges, net in the consolidated statements of income. The Company recognized $22 million and $104 million of certain litigation charges during the three and nine months ended January 24, 2025, respectively, whereas the Company recognized no certain litigation charges and $105 million of certain litigation charges during the three and nine months ended January 26, 2024, respectively. At January 24, 2025 and April 26, 2024, accrued litigation was approximately $0.2 billion. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other accrued expenses and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
Intellectual Property Matters
Colibri
The Company is a defendant in patent litigation brought by Colibri Heart Valve LLC (Colibri) in the U.S. District Court for the Central District of California. Colibri alleges infringement of one patent by the Company’s Evolut family of transcatheter aortic valve replacement devices. The patent asserted by Colibri has expired. On February 8, 2023, a jury returned a verdict against the Company for approximately $106 million. In July 2023, the Company filed its appeal with the U.S. Court of Appeals for the Federal Circuit. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable.
Product Liability Matters
Hernia Mesh Litigation
Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts that allege personal injury from hernia mesh products sold by those subsidiaries. As of January 22, 2025, the Company and certain of its subsidiaries have been named as defendants in lawsuits filed on behalf of approximately 8,950 individual plaintiffs, and certain plaintiffs’ law firms have advised the Company that they may file additional cases in the future. Approximately 6,900 plaintiffs have pending lawsuits in a coordinated proceeding in Massachusetts state court, where they have been consolidated before a single judge. Approximately 500 plaintiffs have pending lawsuits in a coordinated action in Minnesota state court, and there are approximately 1,550 actions coordinated in a federal Multidistrict Litigation in the U.S. District Court for the District of Massachusetts plus fewer than ten one-off cases filed in other courts. The pending lawsuits relate almost entirely to hernia mesh products that have not been subject to recalls, withdrawals, or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.
Diabetes Pump Retainer Ring Litigation
Starting in fiscal year 2021, plaintiffs began filing lawsuits against the Diabetes operating unit in U.S. state and federal courts alleging personal injury from Series 600 insulin pumps with allegedly defective clear retainer rings that were subject to field corrective actions in 2019 and 2021. As of January 28, 2025, after a number of recent dismissals, there are 15 lawsuits filed on behalf of 35 individuals. Plaintiffs’ firms previously notified the Company that they may file additional lawsuits in the future on behalf of several thousand additional claimants. Most of the filed suits are coordinated in California state court. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.
Antitrust Matters
Applied Medical
The Company is a defendant in civil antitrust litigation brought by Applied Medical Resources Corporation in the U.S. District Court for the Central District of California, alleging that the Company has engaged in anticompetitive and monopolistic conduct relating to its sales of advanced bipolar devices, including under contracts with group purchasing organizations. The Company has substantial legal and factual defenses and intends to defend itself vigorously. The matter is currently scheduled for jury trial in June 2025. The Company has not recorded an expense related to damages in connection with this matter because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter.
Environmental Proceedings
The Company is a successor to several investigation and cleanup actions at various stages related to environmental remediation matters at a number of sites, including in Orrington, Maine. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.
The Company is also a successor to a party named in a lawsuit filed in the U.S. District Court for the District of Maine in the early 2000's by the Natural Resources Defense Council and the Maine People's Alliance relating to mercury contamination of the Penobscot River and Bay and options for remediating such contamination. In October 2022, the court issued a final order approving the settlement and the parties are working with consultants on implementation of remedial activities. The final court order did not result in a change to the Company's previous accrual for this matter.
The Company's accrued expenses for these various environmental proceedings are included within accrued litigation as discussed above.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
Anti-Corruption Matters
The Company has regular and ongoing interactions with governmental agencies, and its practice is to cooperate with such inquiries. In addition, from time to time, the Company self-discloses potential concerns to governmental regulators. Like many in the medical device industry or with international operations, the Company engages in periodic discussions with the U.S. Securities and Exchange Commission, U.S. Department of Justice, and various authorities in China regarding certain activities in certain foreign countries, including China. The Company is committed to regularly evaluating and, as appropriate, strengthening its anti-corruption compliance programs and practices. Any possible future determination that certain of our operations and activities, and/or those of our third-party distributors, are not in compliance with existing laws could result in the imposition of fines, penalties, and equitable remedies in the United States or in other jurisdictions. The Company has not recorded an expense in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.
Other Matters
Italian Payback
In 2015, “payback” legislation was enacted in Italy requiring companies selling medical devices to make payments to the Italian state if Italy’s medical device expenditures exceed annual regional maximum ceilings. The payment amounts are calculated based upon the amount by which the regional ceilings were exceeded for any given year. There has been significant scrutiny on the legality and enforceability of the payback law since its inception, and litigation challenging the law has been proceeding through the Italian Courts. Since the law was enacted, the Company has recognized an estimate for the amount of variable consideration but has not made any payments under the payback law. In July 2024, two rulings by the Constitutional Court of Italy found that the medical device payback law is constitutional. Therefore, the Company increased its liability pertaining primarily to certain prior years since 2015 by $90 million during the three months ended July 26, 2024, as a reduction to net sales in the consolidated statements of income. As litigation before Italian Courts is still pending, final resolution is unknown at this time, and it is possible that the amount of the Company’s liability could differ from the amount currently accrued.
Income Taxes
In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court (Tax Court) reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006 whereby it generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit regarding the Tax Court opinion. The U.S. Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings. The Tax Court issued its second opinion in August 2022, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit in September 2023, and Medtronic subsequently filed a cross-appeal in October 2023.
The IRS has issued its audit reports on Medtronic, Inc. for fiscal years 2007 through 2016. Medtronic, Inc. and the IRS have reached agreement on all significant issues except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court matter for fiscal years 2005 and 2006.
Medtronic, Inc.’s fiscal years 2017, 2018, and 2019 U.S. federal income tax returns are currently being audited by the IRS.
Covidien LP (a wholly owned subsidiary of Medtronic plc) has either reached agreement with the IRS or the statute of limitations has lapsed on its U.S. federal income tax returns through fiscal year 2021.
Although it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows.
Refer to Note 11 for additional discussion of income taxes.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
Guarantees
In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.
The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, and/or cash flows.
17. Segment and Geographic Information
Segment disclosures are on a performance basis consistent with internal management reporting. Net sales of the Company's reportable segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. The Company’s management evaluates performance of the segments and allocates resources based on net sales and segment operating profit. Segment operating profit represents income before income taxes, excluding interest income or expense, amortization of intangible assets, centralized distribution costs, currency impact of remeasurement and hedging, non-operating income or expense items, certain corporate charges, stock-based compensation, and other items not allocated to the segments.
The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment.
There have been no changes to reportable segments during the three and nine months ended January 24, 2025. We continue to have four reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. Prior period amounts have been recast to conform to the new operating segment structure in the fourth quarter of fiscal year 2024. For further information on the operating segment structure changes, refer to Note 19 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024.
Medtronic plc
Notes to Consolidated Financial Statements
(Unaudited)
The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements:
Segment Operating Profit
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||
| Cardiovascular | $ | 1,205 | $ | 1,090 | $ | 3,494 | $ | 3,298 | |||||||||||||||
| Neuroscience | 1,061 | 994 | 3,046 | 2,853 | |||||||||||||||||||
| Medical Surgical | 765 | 812 | 2,229 | 2,332 | |||||||||||||||||||
| Diabetes | 136 | 118 | 354 | 304 | |||||||||||||||||||
| Reportable segment operating profit | 3,167 | 3,014 | 9,123 | 8,787 | |||||||||||||||||||
| Other operating segment(1) | 13 | 7 | 39 | 8 | |||||||||||||||||||
| Corporate | (481) | (466) | (1,383) | (1,345) | |||||||||||||||||||
| Interest expense, net | (179) | (188) | (555) | (517) | |||||||||||||||||||
| Other non-operating income, net | 72 | 177 | 403 | 407 | |||||||||||||||||||
| Amortization of intangible assets | (416) | (419) | (1,243) | (1,274) | |||||||||||||||||||
| Stock-based compensation | (98) | (85) | (340) | (303) | |||||||||||||||||||
| Centralized distribution costs | (445) | (415) | (1,244) | (1,202) | |||||||||||||||||||
| Currency(2) | 12 | (12) | (32) | 16 | |||||||||||||||||||
| Restructuring and associated costs | (46) | (55) | (154) | (237) | |||||||||||||||||||
| Acquisition and divestiture-related items | (28) | (58) | (15) | (165) | |||||||||||||||||||
| Certain litigation charges, net | (22) | — | (104) | (105) | |||||||||||||||||||
| Medical device regulations | (11) | (26) | (38) | (88) | |||||||||||||||||||
| Other adjustments(3) | — | — | (90) | — | |||||||||||||||||||
| Income before income taxes | $ | 1,540 | $ | 1,472 | $ | 4,367 | $ | 3,982 |
(1)Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested.
(2)Includes the net impact of remeasurement and the Company's hedging programs recorded in other operating (income) expense, net.
(3)Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.
Geographic Information
Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. The following table presents net sales for the three and nine months ended January 24, 2025 and January 26, 2024 for the Company's country of domicile, countries with significant concentrations, and all other countries:
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | January 24, 2025 | January 26, 2024 | January 24, 2025 | January 26, 2024 | |||||||||||||||||||
| Ireland | $ | 28 | $ | 27 | $ | 86 | $ | 86 | |||||||||||||||
| United States | 4,237 | 4,120 | 12,624 | 12,219 | |||||||||||||||||||
| Rest of world | 4,027 | 3,942 | 11,900 | 11,470 | |||||||||||||||||||
| Total other countries, excluding Ireland | 8,264 | 8,062 | 24,524 | 23,689 | |||||||||||||||||||
| Total | $ | 8,292 | $ | 8,089 | $ | 24,610 | $ | 23,775 |
Previous: Cover and table of contents · Next: Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations